Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
Infusions of Vertex's Casgevy and bluebird bio's Lyfgenia for sickle cell treatment have begun, marking a breakthrough. Both companies face a slow uptake due to the lengthy treatment process, but interest is high. Vertex aims to activate 75 centers globally, while bluebird expects a consistent revenue stream from Lyfgenia.
Reference News
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
Infusions of Vertex's Casgevy and bluebird bio's Lyfgenia for sickle cell treatment have begun, marking a breakthrough. Both companies face a slow uptake due to the lengthy treatment process, but interest is high. Vertex aims to activate 75 centers globally, while bluebird expects a consistent revenue stream from Lyfgenia.